Canada markets open in 5 hours 44 minutes

CSPC Pharmaceutical Group Limited (CVG.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.9790+0.0054 (+0.55%)
As of 08:05AM CEST. Market open.

CSPC Pharmaceutical Group Limited

No. 226 Huanghe Street
Shijiazhuang 050035
China
86 31 1870 37015
https://www.cspc.com.hk

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full Time Employees25,147

Key Executives

NameTitlePayExercisedYear Born
Mr. Dongchen CaiExec. Chairman1.86MN/A1954
Mr. Cuilong ZhangVice-Chairman & CEO1.28MN/A1969
Mr. Chunlei LiExec. Director & Chief Scientist695.99kN/A1976
Mr. Kin Man ChakExec. Director700.62kN/A1966
Mr. Weidong PanExec. Director701.6kN/A1970
Mr. Huaiyu WangExec. Director695.43kN/A1963
Mr. Zhenguo WangExec. Director695.43kN/A1970
Dr. Qingxi WangExec. Director243.78kN/A1966
Dr. Hao JiangExec. Director701.74kN/A1983
Mr. Jinxu WangSr. VPN/AN/A1971
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

Corporate Governance

CSPC Pharmaceutical Group Limited’s ISS Governance QualityScore as of September 1, 2022 is 8. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 2; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.